News Column

Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program

July 30, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Headline of release should read: Actinium Pharmaceuticals, Inc.Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program). Subhead of release should read: Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies (instead of Actinium Pharmaceuticals Initiates Development Of Actinium 225 Labeled Antibody For Hematologic Malignancies). Also, a sentence was added to the end of the first paragraph (see also Actinium Pharmaceuticals, Inc.).

The corrected release reads: ACTINIUM PHARMACEUTICALS, INC. LAUNCHES DEVELOPMENT OF ANTIBODY ACTINIUM-225 LABELING CONSTRUCT TO SUPPORT THIRD CLINICAL PROGRAM Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has the potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Assuming success of this program, Actinium will select the appropriate indication for clinical development of the new construct.

"We continue to work with leading institutions including Memorial Sloan Kettering to leverage the broad utility of our alpha particle immunotherapy platform, a highly potent and selective form of targeted radiotherapy, to address significant unmet patient need in various cancer types", commented Dr. Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals. "Clinical trials of drug candidates based on alpha emitting isotopes have demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. If successful, we believe this approach will further expand the field of use of alpha emitters."

Arming a versatile antibody with actinium-225 will allow further customization of treatment in various blood cancer indications and its use in expanded clinical settings due to very low levels of radiation exposure to medical personnel, other caregivers and environment. Pending successful results of the preclinical work, development will continue in clinical trials.

Keywords for this news article include: Actinium Pharmaceuticals, Actinium Pharmaceuticals Inc., Antibodies, Blood Proteins, Cancer, Clinical Trials and Studies, Immunoglobulins, Immunology, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters